About this event

  • Date and time Mon 4 Mar 2019 from 9:00am to 6:00pm
  • Location Royal Society of Medicine
  • Organised by Pathology

This meeting will present delegates with an understanding of major advances in the fields of personalised cellular therapy and stem cell transplantation, for NHS patients with cancer and autoimmune disease.

Session one will focus on autologous stem cell transplantation for autoimmune diseases, including multiple sclerosis and systemic sclerosis.

Session two will focus on immune effector cell therapy, using genetically modified patients cell to produce chimeric antigen receptor T (CAR-T) cells for NHS patients with cancer, particularly blood cancers including leukaemia and lymphoma. This is personalised cellular therapy.

The faculty includes expert clinicians and scientists that are world leaders in the field. The challenges to accessing treatment in the NHS will also be discussed by the expert panel, with reference to NHS England and clinical commissioning group commissioning, the Cancer Drugs Fund (CDF), and NICE.

Topics include:

  • Multiple sclerosis, systemic sclerosis and other autoimmune diseases as indications for autologous stem cell transplantation
  • Autologous stem cell transplantation mechanisms and access in the NHS for patients with autoimmune conditions
  • Leukaemia and lymphoma as indications for CAR-T cell therapy
  • Establishing a CAR-T cell therapy service in the NHS for blood and solid cancer, and advances in the field
  • Management of early and late complications post CAR-T cell therapy, focussing on intensive care unit (ICU) support
  • Access to CAR-T cell therapy in the NHS

Key speakers

Richard Burt

Professor Richard Burt

Chief of Immunotherapy and Autoimmune Diseases in the Department of Medicine at Northwestern Feinberg School of Medicine in Chicago, Illinois, USA

Speaker's biography

Professor Burt's Department, the Division of Immunotherapy and Autoimmune Diseases (DIAD) is the only centre in the world devoted to a unique area of treatment and research utilizing stem cell transplantation in clinical trials for autoimmune diseases and vascular diseases. DIAD pioneered and performed America’s first hematopoietic stem cell transplants to treat: Multiple Sclerosis (MS), Diabetes, Lupus, Crohn’s, Rheumatoid Arthritis, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Phemphigus, Dermatomyositis, Devic’s, Myasthenia Gravis, Polymositis and Scleroderma.

His lecture titled “An update on the MIST (Multiple sclerosis International Stem cell Transplantation) trial” will provide information on the aims and the outcomes of the first and only trial of its kind testing haematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis. As an investigator involved in the trial, Professor Burt can provide unique insights into what this trial means for the future of MS treatment. While the first part of the study demonstrated that this type of stem cell transplantation can be delivered with acceptable safety, the longer-term evaluation is still underway until 2021 and thus an update on the MIST trial will be of great interest to an international audience. Professor Burt will also participate in the panel discussion titled “Should stem cell transplantation be the first-line treatment for multiple sclerosis.” 

Agenda

View the programme

Registration, tea and coffee
Welcome and introduction

Dr Amit Patel, President, Pathology Section, Royal Society of Medicine

Session one

Stem Cell Transplantation for Autoimmunity; Multiple Sclerosis (MS), Systemic Sclerosis, and Other Diseases

Living with MS, MS Society

Lynn Yambao, Patient

How does haematopoietic stem cell transplantation work for MS?

Professor Paolo Muraro, Imperial College London, UK

KEYNOTE: Clinical experience the evidence of autologous stem cell transplantation for MS

Professor Richard Burt, Northwestern University, USA

Tea and coffee break
Living with systemic sclerosis
How does haematopoietic stem cell transplantation work for scleroderma?

Dr. Voon Ong, University College London

KEYNOTE: Clinical experience and evidence supporting autologous stem cell transplantation in autoimmune diseases – a view from the EBMT and the UK

Professor John Snowden, Consultant Haematologist & Director of Blood and Marrow Transplantation, Sheffield Teaching Hospitals NHS Foundation Trust & University of Sheffield UK

 

Panel debate: Should autologous stem cell transplantation be first line treatment for MS and systemic sclerosis?

All speakers

Lunch

Session two

IMMUNE EFFECTOR CELL THERAPY: Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Blood and Solid Cancers

Living with blood cancer
Evidence for CAR-T cell therapy to treat blood cancers

Dr Amit Patel, University of Liverpool, UK

KEYNOTE: Establishing a CAR-T cell therapy service in the NHS for blood and solid cancers

Professor Karl Peggs, University College London, UK

KEYNOTE: Advances in immune effector cell therapies for blood and solid cancers

Dr. Martin Pule, University College London, UK

Tea and coffee break
Managing complications of CAR-T cell therapy in the intensive care unit (ICU)

Dr Victoria Metaxa, King’s College Hospital, London, UK

Managing complications and late effects post CAR-T cell therapy: 30 days and beyond

Dr Amit Patel

Panel discussion: Access to CAR-T cell therapy for blood cancers in the NHS.

All speakers

Closing remarks

Dr Amit Patel

Close of meeting

Evaluation surveys and certificates will be sent by email

Student and trainee question and answers session

All speakers

Close of meeting student and trainee session

Location

Royal Society of Medicine, 1 Wimpole St, Marylebone, London, W1G 0AE, United Kingdom

Other events of interest

DNM04 Promo
CPD

Spotlight on whistleblowing

This meeting will bring together policy-makers, researchers, clinicians and other healthcare professionals to understand the climate for whistleblowers within the NHS.

  • Price £12 - £60
  • Location Royal Society of Medicine, 1 Wimpole St, Marylebone, London, W1G 0AE, United Kingdom